LONDON - Shortwave Life Sciences PLC, a biopharmaceutical firm based in the UK, is set to initiate a crowdfunding campaign to fund the development of a new treatment for anorexia nervosa. The company's innovative approach, which includes a psilocybin-based drug and a proprietary buccal film delivery system, is designed to enhance patient outcomes for this serious eating disorder that currently lacks FDA-approved pharmaceutical remedies.
The pre-launch of the crowdfunding on Crowdcube is part of Shortwave's strategy to advance its treatment options into clinical trials. By partnering with Sheba Medical (TASE:PMCN) Center in Israel, a leader in the treatment of eating disorders, Shortwave aims to support its Phase 1 clinical trials and further its research initiatives.
Shortwave's buccal film technology is reported to offer improved absorption, addressing common delivery challenges faced by anorexia patients. The funds from the crowdfunding campaign are intended to help the company complete pre-clinical trials, enter Phase 1 human trials, and continue developing its intellectual property and drug pipeline.
Rivki Stern (AS:PBHP), CEO of Shortwave, emphasized the urgency for innovative solutions in mental health care and invited investors to contribute to the effort. The crowdfunding campaign provides a chance for investors to back research that could significantly impact the treatment of anorexia nervosa while gaining equity in a company at the cutting edge of mental health treatment.
Shortwave Life Sciences is focused on creating therapies for unaddressed medical needs in mental health. The company prides itself on its dedication to developing groundbreaking therapies that could potentially reshape mental health care.
This announcement is based on a press release statement by Shortwave Life Sciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.